Skip to main content
An official website of the United States government

Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Please check the “Other Notices” tab on the NIH Guide for Grants and Contracts to see updates to NIH policies that ensure alignment with the Administration’s priorities.

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes PAR-25-095 (R01 Clinical Trial Not Allowed) R01 Clinical Trial Not Allowed 09/07/2026 Wendy Wang, Ph.D., M.Sc.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/14/2026 Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-075 (UH3 Clinical Trials Not Allowed) UH3 10/14/2026 Sudhir Srivastava, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed) R00, K99 Clinical Trial Not Allowed 10/15/2026 Asad Umar, D.V.M., Ph.D.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-287 (K99/R00 - Independent Clinical Trial Required) R00, K99 Clinical Trial Required 10/15/2026 Asad Umar, D.V.M., Ph.D.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required) R00, K99 10/15/2026 Asad Umar, D.V.M., Ph.D.
Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/07/2027 Goli Samimi, Ph.D., M.P.H.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-070 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 01/07/2027 Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-069 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/07/2027 Edward Sauter, M.D., Ph.D.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis PAR-25-081 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/07/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H.